Compare ESEA & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESEA | ZVRA |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.2M | 472.9M |
| IPO Year | 2005 | 2015 |
| Metric | ESEA | ZVRA |
|---|---|---|
| Price | $68.59 | $10.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $62.00 | $23.00 |
| AVG Volume (30 Days) | 60.2K | ★ 712.5K |
| Earning Date | 06-17-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $1.74 | $37.27 |
| Revenue Next Year | $1.07 | $53.42 |
| P/E Ratio | ★ $3.39 | $7.46 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $33.88 | $7.16 |
| 52 Week High | $74.75 | $13.16 |
| Indicator | ESEA | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 52.59 |
| Support Level | $51.63 | $8.25 |
| Resistance Level | $72.82 | $11.07 |
| Average True Range (ATR) | 2.95 | 0.41 |
| MACD | -0.23 | -0.05 |
| Stochastic Oscillator | 24.82 | 39.32 |
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.